Series BVenture Capital
Kailera Therapeutics Secures $600M Series B Funding Led by Bain Capital Private Equity
•November 7, 2025
•Nov 7, 2025
0
Participants
Kailera Therapeutics
company
Qatar Investment Authority
investor
Janus Henderson Investors
investor
RTW Investments
investor
Invus
investor
Bain Capital Life Sciences
investor
Atlas Venture
investor
Cppib
investor
Royalty Pharma
investor
Bain Capital Private Equity
investor
T. Rowe Price
investor
Adage Capital
investor
Citadel
investor
Perseverance Capital
investor
Sirona
investor
Why It Matters
The large raise signals strong market confidence in obesity treatments and equips Kailera to advance a potentially market‑changing weight‑loss drug through late‑stage trials, positioning it for a significant commercial opportunity.
Deal Summary
Kailera Therapeutics announced a $600 million Series B round to advance its obesity drug pipeline, with Bain Capital Private Equity as the lead investor. The round also attracted a slate of institutional investors including CPP Investments, Qatar Investment Authority, and Royalty Pharma, among others.
0
Comments
Want to join the conversation?
Loading comments...